- Trials with a EudraCT protocol (23)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
23 result(s) found for: Chronicity.
Displaying page 1 of 2.
EudraCT Number: 2016-000316-15 | Sponsor Protocol Number: 523079.01.114 | Start Date*: 2016-09-17 | |||||||||||
Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG | |||||||||||||
Full Title: Clinical Trial to Explore Treatment Effects of Ginkgo biloba Extract EGb 761® in Patients with Different Types of Vertigo and Effect Modification by Type of Vertigo, Chronicity and Concomitant Path... | |||||||||||||
Medical condition: Different types of vertigo | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001249-37 | Sponsor Protocol Number: 73763989HPB2004 | Start Date*: 2020-12-17 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo‑controlled Study with Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ-73763989 + Nucleos(t)ide A... | |||||||||||||
Medical condition: Hepatitis B and Hepatitis D Viral Co-infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Completed) SE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002819-60 | Sponsor Protocol Number: FAC-BOTOX | Start Date*: 2021-08-19 |
Sponsor Name:Hospital Universitario de Burgos | ||
Full Title: Treatment of chronic anal fissure with ultrasound-guided intersphincteric infiltration of botulinum toxin A. | ||
Medical condition: Chronic anal fissure | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000492-32 | Sponsor Protocol Number: T16/2013 | Start Date*: 2013-07-10 |
Sponsor Name:Turku University Hospital | ||
Full Title: T cell and interferon expression in tonsils after sublingual immunotherapy and/or nasal live attenuated influenza vaccine | ||
Medical condition: We investigate the effects of allergen and virus on patients with recurrent tonsillitis or tonsillar hypertrphy. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004148-31 | Sponsor Protocol Number: PREDMETH_NL71782.078.19 | Start Date*: 2020-02-26 |
Sponsor Name:Erasmus Medisch Centrum Dept. of Pulmonology | ||
Full Title: The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial | ||
Medical condition: pulmonary sarcoidosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000622-22 | Sponsor Protocol Number: 73763989HPB2001 | Start Date*: 2019-08-20 | |||||||||||
Sponsor Name:Janssen Sciences Ireland UC | |||||||||||||
Full Title: A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for th... | |||||||||||||
Medical condition: Chronic Hepatitis B Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) CZ (Completed) ES (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004649-28 | Sponsor Protocol Number: CTO-201 | Start Date*: 2015-10-09 |
Sponsor Name:Matrizyme Pharma Corporation | ||
Full Title: A 2-stage study to evaluate single doses of MZ-004 at different dose levels in patients with chronic total occlusions. STAGE 1: Open label Training Stage. STAGE 2: Double-blind, randomized, Pla... | ||
Medical condition: The use of MZ-004 to facilitate percutaneous coronary intervention in symptomatic patients with a chronic total occlusion who are indicated for revascularization | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004253-24 | Sponsor Protocol Number: CLNP023B12001B | Start Date*: 2019-08-28 |
Sponsor Name:Novartis Pharma AG | ||
Full Title: An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy | ||
Medical condition: C3 Glomerulopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000570-35 | Sponsor Protocol Number: 01-2015 | Start Date*: 2016-02-10 | |||||||||||||||||||||
Sponsor Name:DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II | |||||||||||||||||||||||
Full Title: Prophylaxis of Hepatitis B reactivation in patients with HBV occult infection and rheumatological diseases candidates to immune suppressive treatments of finite duration. | |||||||||||||||||||||||
Medical condition: Occult Hepatitis B virus Infection (OBI) in patients with rheumatologic diseases candidate to treatment a finite duration (less than 18 months) with potent immune suppressive drugs | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-005213-11 | Sponsor Protocol Number: NES103694 | Start Date*: 2005-03-31 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A multi-centre, randomised, double-blind, parallel group study assessing the efficacy and safety of IV nesiritide versus placebo, in addition to background care, in the treatment of subjects with a... | |||||||||||||
Medical condition: Acute decompensated heart failure (adHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) IE (Completed) SK (Completed) HU (Prematurely Ended) IS (Prematurely Ended) CZ (Prematurely Ended) LT (Prematurely Ended) DK (Completed) LV (Completed) EE (Completed) FI (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004475-39 | Sponsor Protocol Number: 73763989HPB2003 | Start Date*: 2020-09-21 | |||||||||||
Sponsor Name:Janssen Sciences Ireland Unlimited Company | |||||||||||||
Full Title: A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing... | |||||||||||||
Medical condition: Chronic Hepatitis B Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) DE (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004978-26 | Sponsor Protocol Number: 73763989PAHPB2005 | Start Date*: 2020-10-12 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, randomized, open-label, multicenter study to evaluate efficacy, pharmacokinetics, safety, and tolerability of response-guided treatment with JNJ-73763989 + JNJ-56136379 + nucleos(t)ide a... | |||||||||||||
Medical condition: Chronic Hepatitis B Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003956-34 | Sponsor Protocol Number: 73763989PAHPB2006 | Start Date*: 2021-01-16 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)ide Analogs, and Pegylate... | |||||||||||||
Medical condition: Chronic Hepatitis B Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000315-32 | Sponsor Protocol Number: 523079.01.113 | Start Date*: 2016-09-02 | |||||||||||
Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG | |||||||||||||
Full Title: Clinical Trial to Explore Treatment Effects of Ginkgo biloba Extract EGb 761® in Patients with Chronic Tinnitus and Effect Modification by Etiology, Biological Factors and Concomitant Pathologies. | |||||||||||||
Medical condition: Chronic Tinnitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002882-20 | Sponsor Protocol Number: | Start Date*: 2019-04-17 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: A multicentre randomised controlled trial to assess the safety and efficacy of adding rituximab to standard of care in treating acute antibody-mediated rejection in kidney transplantation (Transpla... | |||||||||||||
Medical condition: Renal Transplant antibody-mediated rejection | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001171-23 | Sponsor Protocol Number: ON/2016/6004 | Start Date*: 2017-06-26 |
Sponsor Name:University Hospitals Bristol NHS Foundation Trust | ||
Full Title: A multicentre randomised trial of First Line treatment pathways for newly diagnosed Immune Thrombocytopenia: Standard steroid treatment versus combined steroid and mycophenolate. | ||
Medical condition: Immune Thrombocytopenia | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2017-001821-42 | Sponsor Protocol Number: CL011_168 | Start Date*: 2018-08-02 | |||||||||||
Sponsor Name:ChemoCentryx, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy | |||||||||||||
Medical condition: C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, fo... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) NL (Completed) ES (Completed) DK (Completed) FR (Completed) IT (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004527-31 | Sponsor Protocol Number: GS-US-196-0103 | Start Date*: 2008-12-12 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and... | |||||||||||||
Medical condition: Genotype-1 Chronic Hepatitis C Virus (HCV) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) GB (Completed) DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002674-31 | Sponsor Protocol Number: 73763989PAHPB2002 | Start Date*: 2019-12-16 | |||||||||||
Sponsor Name:Janssen Sciences Ireland UC | |||||||||||||
Full Title: A Randomized, Double blind, Placebo-controlled Phase 2b Study to Evaluate Efficacy, Pharmacokinetics, and Safety of 48-week Study Intervention With JNJ-73763989+JNJ-56136379+Nucleos(t)ide Analog (N... | |||||||||||||
Medical condition: Chronic Hepatitis B Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) FR (Completed) PL (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020033-14 | Sponsor Protocol Number: CDEB025A2210 | Start Date*: 2010-09-03 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicentre, randomized, double-blind, placebocontrolled, parallel-group phase II study on efficacy and safety of DEB025 combined with peg-IFN alfa-2a and ribavirin in chronic hepatitis C genotyp... | |||||||||||||
Medical condition: Chronic Hepatitis C Genotype 1 patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) DE (Completed) FR (Completed) ES (Completed) BE (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
